PDS Biotechnology (NASDAQ:PDSB) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of PDS Biotechnology (NASDAQ:PDSB) from a sell rating to a hold rating in a research note issued to investors on Saturday.

A number of other equities analysts have also recently weighed in on PDSB. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of PDS Biotechnology in a report on Wednesday, April 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PDS Biotechnology in a research note on Friday, July 17th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, PDS Biotechnology has an average rating of “Hold” and a consensus target price of $9.00.

PDS Biotechnology Stock Up 3.8%

PDSB opened at $0.78 on Friday. The business’s fifty day simple moving average is $0.86 and its 200 day simple moving average is $0.87. PDS Biotechnology has a 52 week low of $0.51 and a 52 week high of $1.55. The company has a quick ratio of 2.26, a current ratio of 2.26 and a debt-to-equity ratio of 2.73. The stock has a market cap of $43.36 million, a PE ratio of -1.16 and a beta of 1.62.

PDS Biotechnology (NASDAQ:PDSB) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.02. As a group, research analysts expect that PDS Biotechnology will post -0.52 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC bought a new stake in shares of PDS Biotechnology in the 4th quarter valued at about $25,000. Marshall Wace LLP bought a new position in PDS Biotechnology during the 2nd quarter worth approximately $91,000. Bank of New York Mellon Corp purchased a new position in PDS Biotechnology in the 2nd quarter worth approximately $60,000. Jane Street Group LLC purchased a new position in PDS Biotechnology in the 2nd quarter worth approximately $92,000. Finally, Susquehanna International Group LLP lifted its position in PDS Biotechnology by 603.7% in the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock valued at $95,000 after purchasing an additional 80,937 shares during the last quarter. 26.84% of the stock is owned by institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.